Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025363 · ClinicalTrials.gov registry record · Phase 2
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00025363: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00025363 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025363, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have rhabdomyosarcoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells
Interventions
- DRUG cyclophosphamide
- DRUG ifosfamide
- DRUG doxorubicin hydrochloride
- DRUG irinotecan hydrochloride
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025363
The ClinicalTrials.gov registry entry for NCT00025363 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00025363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025363 about?
NCT00025363 is a clinical study titled "Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma". Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have rhabdomyosarcoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill...
What is the current status of trial NCT00025363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2001-11.
What interventions are being tested in trial NCT00025363?
The interventions under investigation include: cyclophosphamide (DRUG), ifosfamide (DRUG), doxorubicin hydrochloride (DRUG), irinotecan hydrochloride (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00025363?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.